Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Zelgen Biopharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Alopecia Areata

Treatments: Drug: Jaktinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT05255237

ZGJAK020

Details and patient eligibility

About

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".

Enrollment: 315 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects voluntarily sign the informed consent form.
• Patients who participated in ZGJAK018.

Exclusion criteria

• Subjects who are unsuitable to the trial, as identified by the investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

315 participants in 1 patient group

Jaktinib

Experimental group

Description:

Patients will administer the study product twice per day for 24 weeks, for the safety assessment.

Treatment:

Drug: Jaktinib